Engineering Fully Human Monoclonal Antibodies from Murine Variable Regions
Matthew J. Bernett(Xencor (United States)), Greg A. Lazar(Xencor (United States)), Jonathan Zalevsky(Nektar Therapeutics (United States)), John R. Desjarlais(Xencor (United States)), Jonathan Jacinto(Xencor (United States)), Umesh S. Muchhal(IGM Biosciences (United States)), Gregory L. Moore(Xencor (United States)), Duc-Hanh T. Nguyen(Xencor (United States)), Irene Leung(Xencor (United States)), Erik Pong(Xencor (United States)), Sher Karki(Xencor (United States)), Hsing Chen(Xencor (United States))
Cited by 52
Related Papers
β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2
|The Journal of Cell Biology|2000|816
Enhanced antibody half-life improves in vivo activity
|Nature Biotechnology|2010|654
JNK and Tumor Necrosis Factor-α Mediate Free Fatty Acid-induced Insulin Resistance in 3T3-L1 Adipocytes
|Journal of Biological Chemistry|2005|403